



Universiteit
Leiden
The Netherlands

Mechanism of Lys6 poly-ubiquitin specificity by the *L. pneumophila* deubiquitinase LotA

Warren, G.D.; Kitao, T.; Franklin, T.G.; Nguyen, J.V.; Geurink, P.P.; Kubori, T.; ... ; Pruneda, J.N.

Citation

Warren, G. D., Kitao, T., Franklin, T. G., Nguyen, J. V., Geurink, P. P., Kubori, T., ... Pruneda, J. N. (2023). Mechanism of Lys6 poly-ubiquitin specificity by the *L. pneumophila* deubiquitinase LotA. *Molecular Cell*, 83(1), 105-120.e5. doi:10.1016/j.molcel.2022.11.022

Version: Publisher's Version


License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3750125>

Note: To cite this publication please use the final published version (if applicable).

Mechanism of Lys6 poly-ubiquitin specificity by the *L. pneumophila* deubiquitinase LotA

Graphical abstract



Authors

Gus D. Warren, Tomoe Kitao, Tyler G. Franklin, ..., Tomoko Kubori, Hiroki Nagai, Jonathan N. Pruneda

Correspondence

pruneda@ohsu.edu

In brief

Warren et al. identify a K6-specific deubiquitinase within the *Legionella pneumophila* effector LotA and demonstrate its utility as a research tool. Structural and biochemical work explain the mechanism of LotA activation and specificity. During infection, LotA's deubiquitinase activity guards the *Legionella*-containing vacuole from K6 poly-ubiquitin and VCP recruitment.

Highlights

- *L. pneumophila* LotA encodes two functionally distinct deubiquitinases
- LotA's specificity for K6-linked poly-ubiquitin makes it a valuable research tool
- Structures reveal that K6 specificity arises from substrate-assisted catalysis
- LotA restricts K6 poly-ubiquitin and VCP recruitment during infection



Article

Mechanism of Lys6 poly-ubiquitin specificity by the *L. pneumophila* deubiquitinase LotA

Gus D. Warren,¹ Tomoe Kitao,^{2,5} Tyler G. Franklin,^{1,5} Justine V. Nguyen,¹ Paul P. Geurink,³ Tomoko Kubori,^{2,4} Hiroki Nagai,^{2,4} and Jonathan N. Pruneda^{1,6,*}

¹Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA

²Department of Microbiology, Graduate School of Medicine, Gifu University, Gifu, Gifu 501-1194, Japan

³Onco Institute, Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, the Netherlands

⁴G-CHAIN, Gifu University, Gifu, Gifu 501-1194, Japan

⁵These authors contributed equally

⁶Lead contact

*Correspondence: pruneda@ohsu.edu

<https://doi.org/10.1016/j.molcel.2022.11.022>

SUMMARY

The versatility of ubiquitination to control vast domains of eukaryotic biology is due, in part, to diversification through differently linked poly-ubiquitin chains. Deciphering signaling roles for some chain types, including those linked via K6, has been stymied by a lack of specificity among the implicated regulatory proteins. Forged through strong evolutionary pressures, pathogenic bacteria have evolved intricate mechanisms to regulate host ubiquitin during infection. Herein, we identify and characterize a deubiquitinase domain of the secreted effector LotA from *Legionella pneumophila* that specifically regulates K6-linked poly-ubiquitin. We demonstrate the utility of LotA for studying K6 poly-ubiquitin signals. We identify the structural basis of LotA activation and poly-ubiquitin specificity and describe an essential “adaptive” ubiquitin-binding domain. Without LotA activity during infection, the *Legionella*-containing vacuole becomes decorated with K6 poly-ubiquitin as well as the AAA ATPase VCP/p97/Cdc48. We propose that LotA’s deubiquitinase activity guards *Legionella*-containing vacuole components from ubiquitin-dependent extraction.

INTRODUCTION

Post-translational regulation with the small protein modifier ubiquitin (Ub) is essential to all eukaryotic life.¹ In humans, hundreds of enzymes tightly regulate protein ubiquitination by defining both the target substrate and the type of modification.² Unlike binary “on-off” modifications such as phosphorylation or acetylation, the Ub signal can be further diversified through the formation of polymeric Ub (polyUb) chains in which any of the seven Lys residues (e.g., K48- or K63-linked chains) or the amino terminus (linear/M1-linked chains) are ubiquitinated. Differently linked polyUb chains code for distinct signaling outcomes, including proteasomal degradation (K48-linked chains), the DNA damage response (K63-linked chains), or innate immune signaling (M1-linked chains).³ Although the existence and importance of all eight possible chain types has been established,^{4–7} signaling outcomes and regulators for half (K6, K27, K29, and K33) remain ill-defined and have thus been coined “atypical” chains.⁸

Among atypical chain types, K6-linked polyUb has remained particularly enigmatic. Whether K6 polyUb serves as a proteasomal degradation signal remains unclear, as levels of K6 chains show little or no increase upon proteasomal inhibition.^{5,9} K6 polyUb accumulates following mitochondrial depolarization, UV-

induced DNA damage, or inhibition of the AAA ATPase VCP/p97/Cdc48.^{10–13} Defining the importance of K6 polyUb in these responses, however, has been clouded by the imprecise specificities of the implicated E3 ligases and deubiquitinases (DUBs). Mitophagy, for example, can be regulated by the E3 ligase Parkin and DUBs USP30 and USP8, and while these enzymes can control levels of K6 polyUb, they also target other chain types including K11, K48, and K63.^{10,14–17} The same is true for the ligase activity of BRCA1 in the DNA damage response,^{18–20} as well as the ligase activity of HUWE1 in targeting substrates for VCP.^{12,13,21} Confidently ascribing a signaling function for K6 polyUb, therefore, awaits discovery of new approaches or enzymes that can more specifically measure and/or perturb it. Such was the case with M1-linked polyUb, prior to the discovery of M1-specific regulators.²²

PolyUb chain specificity is typically achieved through the concerted action of multiple Ub-binding sites. E2 Ub-conjugating enzymes and E3 ligases achieve linkage specificity through specific coordination of two Ub molecules.²³ Within the resulting polyUb chain, Ub molecules are classified as a distal Ub (Ub^{dist}) that is linked via its C terminus onto an amino group of the proximal Ub (Ub^{prox}). For DUBs, specificity is often achieved via Ub-binding sites that oppose the catalytic center,



including an S1 site that binds Ub^{dist} and an S1' site that binds Ub^{prox} in a linkage-specific orientation.²⁴ Linkage-specific regulators have been identified for M1, K11, K48, and K63 polyUb,³ but despite considerable efforts, human enzymes with stringent specificity toward K6 polyUb have thus far evaded detection.

Pathogenic bacteria represent an alternative source of polyUb linkage-specific enzymes. Bacterial pathogens have evolved Ub regulatory enzymes that interfere with human signaling processes during infection, including a number that target specific polyUb chain types.²⁵ In fact, NleL from enterohemorrhagic *Escherichia coli* is the most K6-specific ligase known to date, assembling a 50:50 mixture of K6 and K48 linkages.²⁶ The causative agent of Legionnaires' disease, *Legionella pneumophila*, has evolved numerous mechanisms of disrupting or hijacking host Ub signaling. Of the >300 effector proteins secreted into infected cells via the *L. pneumophila* Dot/Icm type IV secretion system, several dozen regulate host Ub signals,²⁷ including some that target specific polyUb chain types.²⁸ Many Ub-targeted *Legionella* effectors localize to the *Legionella*-containing vacuole (LCV), where they edit the complex "coat" of Ub modifications in order to establish a replicative niche and evade host immune responses.²⁹ One such effector, termed *Legionella* ovarian tumor (OTU)-like protein A (LotA), was reported to contain two catalytic DUB domains with similarity to the human OTU family, as well as DUB activity toward K6, K48, and K63 polyUb.³⁰ Whether and how one of LotA's catalytic OTU domains might be specific toward K6 polyUb, however, remained unknown.

Here, we demonstrate that the two catalytic DUB modules of LotA are separable and have distinct activities and specificities. Remarkably, the first OTU domain of LotA encodes perfect specificity toward K6 polyUb and represents a valuable tool for studying this atypical linkage. To understand the molecular basis for K6 specificity, we determined crystal structures for LotA alone and bound to K6 diUb. Detailed biochemical analyses revealed a multi-step mechanism of LotA activation that endows K6 specificity, which incorporates themes of conformational rearrangement and substrate-assisted catalysis observed in human linkage-specific DUBs. In the process of studying LotA, we discovered a class of Ub-binding domain (UBD) that is adapted across the *Legionella* Lot class as well as an otherwise unrelated DUB from *Orientia tsutsugamushi*. During *L. pneumophila* infection, we find that LotA plays a role in clearing K6 polyUb from the LCV, which prevents downstream recruitment of VCP. We propose that the dual DUB activities of LotA act to guard select components of the LCV from Ub- and VCP-dependent extraction. This work provides a powerful tool for the study of Ub biology and firmly establishes an interesting link for K6 polyUb at the host-pathogen interface.

RESULTS

LotA encodes two catalytic DUB domains with distinct specificities

The Lot class of DUBs encoded by *L. pneumophila* is currently composed of LotA (lpg2248), LotB (lpg1621), LotC (lpg2529), and LotD (lpg0227) and defined by a ~100 amino acid insertion within the OTU domain. The Lot-class insertion domains are

more diverse in primary sequence than the core OTU domains (Figures S1A and S1B), suggesting that they may play a role in determining the various polyUb specificities that have been reported.^{30–35} LotA encodes two Lot-class OTU domains, denoted LotA_N and LotA_M for the N-terminal and middle domains, respectively, followed by the C-terminal LotA_C domain that binds PI(3)P, localizing LotA to the LCV during infection³⁰ (Figure 1A). As reported previously for shorter polyUb chains,³⁰ we observe that full-length LotA is capable of hydrolyzing long polyUb chains composed of a range of different linkage types, including notable activity toward K6-, K48-, and K63-linked substrates (Figure 1B). The sequence relationship between LotA_N and LotA_M is the most distinct observed among the Lot class, with sequence identities of only 19% and 23% within the insertion and OTU domains, respectively (Figures S1A and S1B). To determine whether LotA_N and LotA_M contribute distinct activities to that observed for full-length LotA (Figure 1B),³⁰ we cloned and expressed the isolated domains for biochemical analyses.

Both the LotA_N and LotA_M isolated constructs reacted with the Ub-propargylamide (Ub-PA) activity-based probe, indicating that each are competent for DUB activity (Figure 1C).³⁹ Reactivities of LotA_N and LotA_M with Ub-PA were ablated by mutation of their annotated catalytic cysteine residues, C13 and C303, to alanine (Figures 1A and 1C).³⁰ Surprisingly, although both constructs reacted with the monomeric Ub-PA substrate, neither could cleave the monomeric Ub-KG(TAMRA) fluorescent substrate, or the analogous NEDD8, SUMO1, or ISG15 substrates (a discrepancy that will be discussed further below) (Figures 1D and S1C–S1E).⁴⁰ When incubated with each of the eight canonical (iso)peptide-linked diUb substrates, LotA_N demonstrated remarkable specificity for the K6 linkage type (Figure 1E). In contrast, LotA_M was very inefficient and only showed marginal cleavage of the K6-linked substrate at high concentration after a long incubation period (Figure 1F). As the polyUb chain length has been reported to affect the activities and/or specificities of some DUBs,^{36,41,42} we assembled a panel of seven differently linked tetraUb substrates (lacking only K27). LotA_N again showed exquisite specificity against the K6 linkage, while LotA_M now demonstrated more robust DUB activity, with a distinct preference toward the K48 linkage and lesser activities toward K6 and K63 tetraUb (Figures 1G and 1H). Consistent with observations made with the diUb panel (Figure 1F), LotA_M activity appeared to stall after the tetraUb and triUb were consumed, leaving a diUb product that was stable over time (Figure 1H). These results indicate that LotA_N and LotA_M indeed demonstrate distinct DUB properties, with LotA_N showing exquisite K6 specificity while LotA_M shows a preference toward longer K48-linked polyUb that is likely directed by an additional (S2 or S2') Ub-binding site. Within the context of full-length LotA, the specificity and activity of the LotA_N OTU domain are independent of the LotA_M OTU domain, as a full-length LotA C303A variant demonstrates the same K6 specificity and rate of cleavage as the isolated LotA_N construct (Figures 1I and 1J).

Benchmarking LotA_N as a tool for the study of K6 polyUb

To further characterize the activity of LotA_N toward K6 polyUb, we constructed a fluorescent K6 diUb substrate (see STAR Methods) and monitored cleavage by fluorescence polarization




Figure 1. Separation of LotA deubiquitinase activities

(A) Domain architecture of *L. pneumophila* LotA, with catalytic triad residues annotated for each OTU domain.

(B) Homogeneous assemblies of seven polyUb linkage types were treated with a high concentration (5 μ M) of full-length LotA for 2 h before the reactions were quenched and visualized by anti-Ub western blot.

(C) Coomassie-stained SDS-PAGE gel showing purified constructs of LotA_N (1–300) and LotA_M (287–543), alongside their catalytically inactive variants. Reactivity with the Ub-PA activity-based probe is assessed by a shift in mobility.

(D) Ub-KG(TAMRA) cleavage assay monitored by fluorescence polarization. Activity was measured using 1 μ M LotA_N, 1 μ M LotA_M, or 100 nM USP21 as a control DUB.

(E and F) Gel-based specificity analysis against all eight canonical diUb linkages. Reactions containing the indicated concentrations of LotA_N (E) and LotA_M (F) were sampled at the indicated time points, quenched, and resolved by SDS-PAGE with Coomassie staining.

(G and H) Gel-based specificity analysis against seven tetraUb linkages. Reactions containing the indicated concentrations of LotA_N (G) and LotA_M (H) were sampled at the indicated time points, quenched, and resolved by SDS-PAGE with Coomassie staining. Note that some tetraUb chains migrate differently based on the linkage site, as observed previously.

(I) Homogeneous assemblies of seven polyUb linkage types were treated with a high concentration (5 μ M) of full-length LotA C303A for 2 h before the reactions were quenched and visualized by anti-Ub western blot.

(J) A homogeneous assembly of K6-linked polyUb was treated with either LotA_N or the full-length LotA C303A variant at 25 nM. Reaction samples were collected and visualized by anti-Ub western blot.

See also Figure S1.




Figure 2. Application of LotA_N K6 specificity for UbiCRest analysis

(A) Kinetic parameters of LotA_N (1–300) measured by changes in fluorescence polarization of labeled K6 diUb. Initial rates of diUb cleavage were measured over a range of substrate concentrations and fit to a Michaelis-Menten model. Error bars represent standard deviation over three measurements, each made in triplicate. (B) Gel-based specificity analysis against seven tetraUb linkages. Reactions containing a high concentration (5 μM) of LotA_N were sampled at the indicated time points, quenched, and resolved by SDS-PAGE with Coomassie staining.

(C) Homogeneous assemblies of seven polyUb linkage types were treated with a high concentration (5 μM) of LotA_N for 2 h before the reactions were quenched and visualized by anti-Ub western blot.

(D) UbiCRest analysis of an NleL ligase assembly with 1 μM K6-specific LotA_N, K11-specific Cezanne, K48-specific OTUB1*, K63-specific AMSH*, non-specific vOTU, or the indicated combinations. Reactions were visualized by anti-Ub western blot. Cleavage of NleL-assembled polyUb can be observed by a decrease in the “smear” or by a reappearance of monoUb.

(E) UbiCRest analysis of a HUWE1 ligase assembly with 1 μM K6-specific LotA_N, K11-specific Cezanne, K48-specific OTUB1*, K63-specific AMSH*, non-specific vOTU, or the indicated combinations. Reactions were visualized by anti-Ub western blot. Cleavage of HUWE1-assembled polyUb can be observed by a decrease in the smear or by a reappearance of monoUb.

See also Figure S2.

(FP), as reported previously.^{43–45} Through measuring initial rates of catalysis over a range of substrate concentrations, Michaelis-Menten parameters could be extracted for LotA_N against K6 diUb (Figures 2A and S2A). Despite a relatively high K_M, LotA_N demonstrated an overall catalytic efficiency that is similar to other linkage-specific OTU DUBs, including the K11-specific Cezanne and the M1-specific OTULIN.^{44,46}

To further benchmark the utility of LotA_N as a tool, we tested whether specificity is retained even at high enzyme concentrations. Remarkably, even at very high (5 μM) enzyme concentration against both tetra- and longer polyUb samples, LotA_N exclusively cleaved only K6 linkages (Figures 2B, 2C, and S2B). To test LotA_N’s utility in releasing K6 linkages from complex, heterogeneous mixtures, we tested it alongside other linkage-specific DUBs in several Ub chain restriction (UbiCRest) analyses.^{36–38}

The HECT-like E3 ligase NleL from enterohemorrhagic *Escherichia coli* has been reported to assemble mixed K6 and K48 polyUb chains.^{26,37} Alongside the constitutively activated K48-specific DUB OTUB1*,⁴⁷ LotA_N could indeed confirm this chain

architecture in a UbiCRest assay. Treatment of NleL-assembled polyUb with either LotA_N or OTUB1* resulted in a partial collapse of the polyUb smear down to shorter chains such as diUb, as well as a partial return of the monoUb band, while treatment with either the K11-specific Cezanne or the constitutively activated K63-specific AMSH* had no effect (Figure 2D).⁴⁷ Co-incubation of the linkage-specific DUBs and comparison with the non-specific vOTU revealed the abundance of K6 linkages present in the NleL assembly (Figure 2D).^{36,48}

As a further test, we generated polyUb chains with HUWE1, a human HECT E3 ligase that is reported to assemble a mixture of K6-, K11-, and K48-linked chains.^{13,21,49} Treatment with Cezanne released the largest amount of monoUb, followed by OTUB1*, then LotA_N, and finally AMSH*, which had only a marginal amount of activity (Figure 2E). DUB co-incubation with or without LotA_N showed a slight difference attributable to K6 linkages, especially at the level of released short polyUb products (Figure 2E). Combined treatment of LotA_N, Cezanne, OTUB1*, and AMSH* hydrolyzed the assembled polyUb to a similar extent




Figure 3. Crystal structure of the LotA_N OTU domain

(A) 1.5 Å crystal structure of LotA (1–294) labeled with visible termini, domain architecture, active site, and OTU variable regions (VR1–3) described previously.³² (B) Close-up view of the LotA_N active site with 2[Fo]–[Fc] electron density overlaid at 1σ for catalytic triad residues. Alternate conformations of the C13 side chain (a and b) are observed, whereas density for the H237 imidazole ring is absent. (C) Cleavage of fluorescent K6 diUb by the indicated LotA_N active site variants at 10 nM concentration monitored by fluorescence polarization. (D) Structural overlay of LotA_N (blue), LotA_M (PDB: 7F9X, orange), LotB (PDB: 6KS5, yellow), and LotC (PDB: 7BU0, green). Structures were aligned by their core OTU domains to demonstrate variability in the insertion domains. (E) Close-up views of the LotA_M (PDB: 7F9X), LotB (PDB: 6KS5), LotC (PDB: 6YK8), and Ub-bound LotC (PDB: 7BU0) active sites. Catalytic triad residues are shown in ball-and-stick representation, with hydrogen bonds indicated by dashed lines.

See also Figure S3.

as vOTU, indicating that K11, K48, and K6 linkages form the bulk of HUWE1 products (Figure 2E). Thus, the high level of activity and specificity exhibited by LotA_N makes it a powerful tool that can be used alongside other linkage-specific enzymes to study K6 polyUb.

Structural analysis of LotA_N

The distinctive sequence and catalytic properties of LotA_N warranted structural analysis for comparison with the other Lot-

class DUBs. We determined a 1.5 Å crystal structure of LotA_N residues 1–294 using SAD phasing on bound iodide ions (Figures 3A and S3A; Table 1). Overall, the LotA_N structure resembled other Lot-class DUBs, with a papain-like OTU domain and a characteristic α-helical insertion domain at variable region 1 (VR-1), but additionally revealed several notable features (Figure 3A). First, the catalytic triad, comprised of C13, H237, and N239, was misaligned and beyond hydrogen-bonding distance in the structure. In fact, two conformations of the C13 side chain

Table 1. Data collection and refinement statistics

	LotA _N (1–294)	LotA _N (1–276): K6 diUb
Data collection		
Wavelength	0.979460	0.979460
Space group	<i>P</i> 4 ₁ 2 ₁ 2	<i>P</i> 4 2 2
Cell dimensions		
<i>a</i> , <i>b</i> , <i>c</i> (Å)	86.25, 86.25, 92.30	127.28, 127.28, 77.99
α , β , γ (°)	90, 90, 90	90, 90, 90
Resolution (Å)	39.07–1.50 (1.50–1.53)	38.99–2.80 (2.80–2.95)
<i>R</i> _{merge}	0.035 (0.819)	0.257 (1.15)
<i>I</i> / σI	26.6 (2.2)	6.4 (2.0)
Completeness (%)	99.9 (99.7)	99.9 (100)
Redundancy	6.5 (6.5)	6.5 (6.7)
Phasing		
Method	SAD	MR
SAD resolution	1.50	–
SAD anom completeness	99.6 (99.5)	–
SAD anom multiplicity	3.4 (3.3)	–
SAD FOM	0.733	–
MR search models	–	LotA _N , Ub (PDB: 1UBQ)
Refinement		
Resolution (Å)	35.59–1.50	38.99–2.80
No. unique reflections/test set	56,168/2,895	16,316/822
<i>R</i> _{work} / <i>R</i> _{free}	0.195/0.221	0.207/0.259
No. atoms		
Protein	2,174	3,399
Ligand/ion	19	0
Water	286	59
B-factors		
Protein	32.81	47.04
Ligand/ion	54.93	–
Water	39.12	33.63
RMS deviations		
Bond lengths (Å)	0.006	0.006
Bond angles (°)	0.77	1.04
Ramachandran statistics		
Favored/allowed/outliers	96.7/3.3/0	97.2/2.8/0

Values in parentheses are for highest resolution shell.

were visible in the electron density, whereas no electron density was observed for the H237 imidazole ring (Figure 3B). Despite this, mutation of C13, H237, and to a lesser extent N239 all severely decreased the ability of LotA_N to cleave the fluorescent K6 diUb substrate (Figure 3C).

The core OTU fold of LotA_N closely resembles those of the other Lot-class DUBs (Figure 3D), as well as the most closely related OTU DUBs from humans, viruses, and bacteria outside

of *Legionella*^{31–34,48,50–52} (Figures S3B–S3D). At the putative S1 Ub-binding site, LotA_N more closely follows the other Lot-class DUBs with a large helical domain inserted at VR-1, and minimal structural features at VR-2 and VR-3 compared with other OTU domains³² (Figures 3D and S3B–S3D). All of the Lot-class insertion domains structurally resolved thus far exhibit distinguishing adaptations of an underlying helical substructure and distinct orientations with respect to the OTU domains (Figure 3D), a feature that has been proposed to contribute to the various polyUb specificities observed within this class of DUBs. A closer look at the catalytic triad across Lot-class DUBs reveals that, similar to LotA_N, the active site of LotA_M is also misaligned in the observed crystal structure, whereas the active sites of LotB, LotC, and Ub-bound LotC are all in proper alignment for catalysis (Figure 3E). This discrepancy in alignment is consistent with our observation that neither LotA_N nor LotA_M could cleave the monomeric Ub-KG(TAMRA) substrate (Figure 1D), whereas LotB and the related LotD were previously shown to be active in the same assay.³² This suggests that LotA_N and LotA_M are distinct from other Lot-class DUBs in their requirement for some form of substrate-assisted catalysis akin to that observed previously for the M1-specific DUB OTULIN.⁴⁴

Mechanism of K6 diUb recognition by LotA_N

To understand the molecular basis of LotA_N activation and K6 polyUb specificity, we determined a 2.8 Å crystal structure of LotA_N in complex with K6 diUb by molecular replacement (Figures 4A, S4A, and S4B; Table 1). In the structure, K6 diUb is bound across the LotA_N active site, sandwiched between the OTU core and the helical insertion domain (Figure 4A). In order to preserve the K6 diUb while retaining binding to LotA_N, the active site C13A mutation was used. Despite this, the electron density between the LotA_N-bound Ub molecules more closely supports a structural intermediate just after isopeptide cleavage, with no density connecting the ϵ -amino group of K6 from Ub^{prox} with the carbonyl carbon of G76 in Ub^{dist} (Figure 4B). Rather than cleavage of the K6 linkage, we believe this lack of clear electron density is either due to a shift in register (i.e., Ub^{dist} and Ub^{prox} are bound into the S1' and S1 sites, respectively, of symmetry-related LotA_N molecules) or symmetry averaging across related asymmetric units, as the C terminus of Ub^{prox} is in close proximity to the K6 of a symmetry-related Ub^{dist} (Figure S4C). The symmetry-related expansion of polyUb chains has been observed in other crystal structures⁴⁷ and in this case suggests that LotA_N exhibits endo-DUB activity that can cleave anywhere within a polyUb chain. Although the catalytic C13 is mutated to alanine, the electron density clearly supports proper alignment and hydrogen bond distance of the remaining H237 and N239 triad members (Figure 4B), indicating a structural rearrangement upon K6 diUb binding that will be discussed in more detail below.

In isolation of binding partners, crystallography and solution NMR data support a predominately closed conformation of K6 diUb, in which the Ub^{dist} I36 hydrophobic patch is bound to the Ub^{prox} I44 hydrophobic patch (Figure 4C).^{37,43} In contrast, LotA_N appears to select an open conformation of K6 diUb such that it can interact with the Ub^{dist} I36 patch as well as the I36 and F4 hydrophobic patches of Ub^{prox} (Figure 4C). Selection among heterogeneous K6 diUb conformations appears to be an




Figure 4. Crystal structure of the LotA_N OTU domain bound to K6 diUb

(A) 2.8 Å crystal structure of LotA_N (1–276, blue) bound to K6 diUb (shades of red). The structure is labeled with visible termini, domain architecture, active site, and OTU variable regions (VR1–3).

(B) Close-up view of the K6 diUb-bound LotA_N active site with 2[Fo]–|Fc| electron density overlaid at 1σ for catalytic triad residues. The K6 side chain of Ub_{prox} and C terminus of Ub_{dist} are also shown with overlaid electron density. The LotA_N catalytically inactive C13A variant was used to preserve the diUb linkage.

(C) Crystal structures of K6 diUb in isolation (PDB: 2XK5) and bound to LotA_N, aligned by their Ub_{dist} moieties (top). Availability and orientation of common interaction surfaces are shown, with dashed circles indicating the surfaces utilized by either Ub:Ub or LotA_N:Ub interaction.

(legend continued on next page)

emerging trend of K6-interacting proteins, as distinct K6 diUb structures have been resolved in complexes with an engineered affimer protein, the DUB USP30, the NZF UBD of TAB2, and now also LotA_N (Figure S4D).^{13,16,53}

The interaction with Ub^{dist} at the LotA_N S1 site appears to be mainly driven through an interface between the inserted helical domain at VR-1 and the I36 patch of Ub^{dist} (Figures 4A and 4C). In contrast, the structure of LotC bound to Ub shows a stark ~180° rotation and a primary interface at a nonconserved VR-2 region (Figure 4D). At the core of the interface, an extended loop region of the LotA_N insertion domain slots L128 into a shallow pocket of Ub^{dist} formed between I36, L71, and T7 (Figure 4E). Additional ionic interactions are observed around the periphery, including hydrogen bonds to both R72 and R74 of Ub^{dist} as the C terminus enters the LotA_N active site (Figure 4E). This interface appears to play a minor role in the binding of K6 diUb, as an L128A mutation had minimal effect, and only a severe L128R mutation that introduces a steric clash with the Ub^{dist} I36 patch significantly disrupted LotA_N cleavage of the fluorescent K6 diUb substrate (Figure 4F).

The LotA_N S1' site orients K6 of Ub^{prox} into the active site through interactions with the Ub I36 and F4 hydrophobic patches (Figures 4A and 4C). The human DUB USP30 also recognizes the F4 patch of a K6-linked Ub^{prox}, but in a very different manner involving a ~100° twist (Figures 4G and S4D). In the LotA_N structure, Ub^{prox} is sandwiched between the core OTU and insertion domains and makes a single hydrogen bond to R74 of Ub^{dist} through the carbonyl oxygen of T9 (Figure 4H). The F4 side chain of Ub^{prox} makes van der Waals interactions to the peptide backbone of D10 within the LotA_N OTU core domain (Figure 4H). At the Ub^{prox} I36 patch, F120 and L141 from the LotA_N insertion domain interact with I36, while buried within the interface lies a salt bridge between LotA_N R145 and Ub^{prox} E34. Mutation of these residues in LotA_N had a much more severe impact on K6 diUb cleavage than mutations in the S1 site (Figures 4F and 4I). Reciprocal mutations specifically introduced into Ub^{prox} of K6 diUb (see STAR Methods) showed the strongest cleavage defect with mutation of F4, a modest effect with I36 mutation, and no effect upon mutation of the unutilized I44 site (Figure 4J).

The LotA_N insertion domain makes key contributions to both the S1 and S1' Ub-binding sites required for DUB activity. Despite their differences, the core structures of the Lot-class

insertion domains follow a related underlying four-helix topology (Figures 4K and S4E). By structural comparison using Dali,⁵² the insertion domain of LotA_N is the most similar to LotC over other Lot-class DUBs (Figure S4F). Based on the Ub- and diUb-bound structures of LotC and LotA_N, respectively, it is the distinguishing features of the α 1-2 region that dictate interactions to Ub (Figures S4F–S4H).³⁴ Modeling and mutagenesis studies implicate the α 1-2 regions of LotB and LotA_M in mediating important Ub interactions as well.^{33,50} Interestingly, Dali searches also detected similarity to the VR-1 region of OtDUB, an effector DUB from *Orientia tsutsugamushi* that belongs to the CE clan of cysteine proteases⁵⁴ (Figure S4I). The OtDUB VR-1 region follows the four-helix structural topology conserved among Lot-class DUBs and encodes two Ub-binding sites: one at the edge of helix 3 that forms part of the S1 site to bind Ub^{dist} (Figure S4J) and a second located in the α 1-2 region that binds an additional Ub with unusually high affinity (Figure S4K). Unlike the high-affinity site in the α 1-2 region (Figure S4K), residues at the edge of helix 3 in OtDUB VR-1 are conserved in the LotA_N structure (Figure S4J). Additional binding of Ub at this site in LotA_N, however, would cause steric clash with the Ub^{dist} observed in our structure (Figure S4J). Because of its important roles in Lot-class DUBs as well as OtDUB, we propose to assign the name adaptive UBD, or “A-UBD” for short, to this common four-helix substructure, owing to adaptations of the α 1-2 regions that impart distinctive Ub interactions into a common topological scaffold (Figures 4K and S4E).

Conformational changes leading to LotA_N activation

Comparison of the apo and K6 diUb-bound LotA_N structures revealed several interesting changes. First, the complex structure exhibited a 45° swing of the A-UBD with respect to the core OTU domain, resulting in a more closed conformation (Figure 5A). This swing moves key residues such as L128, F120, and R145 up, forming the S1 and S1' Ub-binding sites that sandwich K6 diUb against the active site (Figures 5B, 4E, and 4H). Movement within the hinge region is required for LotA_N activity, as a stabilizing A193P hinge mutation reduces cleavage of the fluorescent K6 diUb substrate, while an A193G mutation retains the mobility required for function (Figure 5C). Analogous hinge regions can be observed between the core OTU and A-UBDs of other Lot-class DUBs (Figure S5). Comparison of the apo and Ub-bound LotC

(D) Structural overlay of LotA_N (blue) and LotC (PDB: 7BU0, green) bound to their respective distal Ub moieties (red and pink, respectively). The structures are aligned on their core OTU domains and highlight large differences in Ub orientation, insertion domains, and use of variable regions.

(E) Close-up view of the LotA_N S1 site (blue) bound to Ub^{dist} (red). Interacting residues are shown in ball-and-stick representation, with hydrogen bonds indicated by dashed lines.

(F) Cleavage of fluorescent K6 diUb by the indicated LotA_N S1 site variants at 10 nM concentration monitored by fluorescence polarization.

(G) Structural overlay of LotA_N (blue) and human USP30 (PDB: 5OHP, tan) bound to their respective distal Ub moieties (salmon and purple, respectively). The structures are aligned on their core catalytic domains and highlight large differences in Ub orientation and features of their S1' sites.


(H) Close-up view of the LotA_N S1' site (blue) bound to Ub^{prox} (salmon). Interacting residues are shown in ball-and-stick representation, with hydrogen bonds indicated by dashed lines.

(I) Cleavage of fluorescent K6 diUb by the indicated LotA_N S1' site variants at 10 nM concentration monitored by fluorescence polarization. These data were collected in parallel with those presented in (F), and the WT dataset is shown again for reference.

(J) Gel-based LotA_N cleavage assay of K6 diUb variants with indicated Ub^{prox} mutations. Reactions were quenched at the indicated times and visualized by SDS-PAGE with Coomassie staining.

(K) Underlying helical domain architecture of the LotA_N (left) and stereotypical (right) adaptive Ub-binding domain (A-UBD), with helices labeled and the Ub-binding α 1-2 regions shown in color.

See also Figure S4.






Figure 6. LotA_N restriction of K6 polyUb during *L. pneumophila* infection

(A) Representative images of HeLa FcγRII cells infected with the indicated *L. pneumophila* strains at a multiplicity of infection (MOI) of 2 for 4 h. Fixed cells were stained for *L. pneumophila* (red), HA-Ub-K6 (green), and DNA (blue). Arrows indicate the position of a bacterium in each channel. Images were collected at 100× magnification. Scale bars, 10 μm.

(legend continued on next page)

Thus, Ub-binding at the S1' site in the correct, K6-specific orientation activates the LotA_N catalytic center through substrate-assisted catalysis, by which F4 and H68 of Ub^{prox} assist in the proper orientation of the Cys and His loops.

A mechanism of substrate-assisted catalysis is consistent with the observed lack of activity against the monomeric Ub-KG(TAMRA) substrate (Figure 1D), wherein Ub would presumably bind at the S1 site but the attached KG(TAMRA) moiety occupying the S1' site could not serve to activate the catalytic triad. LotA_N can, however, react with the monomeric Ub-PA activity-based probe (Figure 1C). As expected, the Ub-PA reactivity observed in wild-type LotA_N is abolished or severely reduced in the backgrounds of the catalytic C13A or S1-site L128R mutations, respectively (Figure 5F). Unexpectedly, reactivity was also lost in the S1'-site R145L and the hinge A193P mutants (Figure 5F). To test if one molecule of Ub-PA is binding at the S1' site to activate reactivity for a second, we generated an F4A mutant to block any role in activation (see Figures 4J and 5D). Compared with wild-type Ub-PA, reactivity of the F4A mutant is severely reduced (Figure 5G). Addition of wild-type but not F4A Ub (lacking the PA warhead) rescues reactivity of F4A Ub-PA by serving as a dedicated "activator" for substrate-assisted catalysis at the S1' site (Figure 5G). A prerequisite of substrate-assisted catalysis is movement of the LotA_N A-UBD, as the A193P hinge mutant overrides all Ub-PA reactivity (Figure 5G).

LotA_N activity is required for restriction of K6 polyUb at the LCV

LotA, LotB, and LotC have all been shown to edit Ub modifications deposited onto the LCV.^{30,31,34} LotA regulates K6, K48, and K63 polyUb following localization via its C-terminal PI(3)P-binding domain³⁰ (Figure 1A). Whether these signal types are independently regulated by LotA's two OTU domains, however, had not been tested. We constructed *L. pneumophila* strains with genomic *lotA* mutations at either OTU active site (C13S, C303S) for comparison with the wild-type Lp01 and Δ *lotA* strains and performed infections in HeLa-Fc γ R11 cells expressing a reporter for K6 polyUb (see STAR Methods). Compared with the wild-type strain, deletion of *lotA* results in a significant increase in the number of K6-positive LCVs (Figures 6A and 6B). While the LotA_M C303S mutant restricts K6 polyUb like wild type, the LotA_N C13S mutant phenocopies *lotA* deletion (Figures 6A and 6B). These findings are consistent with our *in vitro* specificity analyses (Figures 1E–1H) and suggest a delineation of roles during infection.

As a further test of our structure-guided mechanistic studies, we designed two separate triple-mutant variants of LotA_N:

"FRA" combines S1'-site F120A and R145L with the hinge A193P mutation, while "LRA" combines S1'-site L128R, S1'-site R145L, and hinge A193P mutations. *In vitro*, neither variant could cleave K6 diUb, even at high concentration (Figure S6A). *L. pneumophila* strains carrying either *lotA* triple-mutant variant failed to restrict K6 polyUb (Figures 6C and S6B), demonstrating that the requirements for LotA_N activity *in vitro* hold true during infection.

The importance of LotA DUB activities for *L. pneumophila* growth was tested by infecting mouse bone marrow-derived macrophages (BMDMs) with the various mutagenized strains. As reported previously,³⁰ deletion of *lotA* resulted in no significant defect in *L. pneumophila* intracellular growth in BMDMs, whereas a secretion-deficient Δ *dotA* strain failed to replicate (Figure 6D). Strains carrying integrated catalytic mutations in either LotA_N (C13S) or LotA_M (C303S) behaved similar to wild-type and Δ *lotA* *L. pneumophila*, with no apparent growth phenotype (Figure 6D).

One proposed signaling role for K6 polyUb is as a preferred target for the AAA ATPase VCP/p97/Cdc48, which extracts ubiquitinated targets for degradation. We examined VCP localization following infection with our mutagenized *L. pneumophila* strains. Infection with wild-type *L. pneumophila* resulted in low but significant VCP recruitment to the LCV compared with a secretion-deficient Δ *dotA* strain, as previously observed⁵⁵ (Figures 6E, 6F, and S6C). Loss of DUB activity through *lotA* deletion or double C13S C303S mutation starkly increased VCP recruitment (Figures 6E, 6F, and S6C). Individual LotA_N and LotA_M active site mutants both exhibited significantly more VCP recruitment than wild-type *L. pneumophila*, indicating non-redundant roles (Figures 6E, 6F, and S6C). These findings are consistent with a role for K6- as well as potentially K48- and K63-linked polyUb in recruiting VCP to the LCV during infection.

DISCUSSION

The identification of K6-specific enzymes in humans has proven difficult.^{10,13,16,36,56} Meanwhile, the first OTU domain of *L. pneumophila* LotA is extremely specific and highly active toward K6 polyUb. Perhaps coincidentally, the most K6-specific E3 ligase identified to date, NleL, also originates from bacteria.²⁶ Just as NleL has become an invaluable tool for studying K6 polyUb,³⁷ LotA_N will be equally useful, particularly in applications such as UbiCRest analyses. Prior use of OTUD3 as a K6-targeted DUB has required careful consideration of enzyme concentration and secondary activities.³⁸ We show that LotA_N

(B) Quantitation of K6-positive bacteria shown in (A). Infections were performed in triplicate and each value represents scoring from 100 LCVs. Significance was determined using a Welch's t test.

(C) Quantitation of K6-positive bacteria from HeLa Fc γ R11 cells infected with the indicated *L. pneumophila* strains at an MOI of 2 for 4 h. Infections were performed in triplicate, and each value represents scoring from 100 LCVs. Significance was determined using a Welch's t test.

(D) Luciferase-expressing *L. pneumophila* strains were used to infect mouse BMDMs at an MOI of 0.5. Intracellular growth was monitored via bioluminescence changes over time. The mean relative luminescence unit (RLU) and standard deviation of eight independent experiments are shown.

(E) Representative images of HeLa Fc γ R11 cells infected with the indicated *L. pneumophila* strains at an MOI of 2 for 4 h. Fixed cells were stained for *L. pneumophila* (red), VCP (green), and DNA (blue). Arrows indicate the position of a bacterium in each channel. Images were collected at 100 $\times$ magnification. Scale bars, 10 μ m.

(F) Quantitation of VCP-positive bacteria shown in (E), alongside infections with a secretion-deficient Δ *dotA* strain and strains carrying mutations in the LotA active sites. Infections were performed in triplicate, and each value represents scoring from 100 LCVs. Significance was determined using a Welch's t test.

See also Figure S6.




Figure 7. Model for LotA deubiquitinase activity

Secreted LotA localizes back to the cytosolic face of the LCV via the PI(3)P-binding LotA_C domain. At the LCV, DUB activity of LotA_M restricts long K48 and K63 polyUb. LotA_N is kept inactive by a flexible A-UBD and inactive arrangement of the catalytic triad. Occupying a closed OTU:A-UBD conformation allows formation of an S1' Ub-binding site. Binding of a K6-linked Ub into the S1' site orients the LotA_N catalytic triad, allowing for hydrolysis of K6 polyUb and prevention of VCP recruitment. Created with [BioRender.com](https://www.biorender.com).

maintains K6 specificity even at high concentration against long, complex polyUb chains and will thus be a convenient tool alongside other polyUb-specific DUBs.

The exquisite specificity of LotA_N toward K6 polyUb arises from a blend of regulatory mechanisms (Figure 7). In our apo structure of LotA_N, the open conformation of the A-UBD is incompatible with polyUb binding, and the active site is misaligned. Consistent with inherent flexibility in these regions, the LotA_N Cys loop, His loop, and hinge region all exhibit above average B-factors. Before polyUb binding can occur, flexibility is required in the LotA_N hinge for the A-UBD to swing into position. This *in situ* formation of Ub-binding sites resembles the human DUB Cezanne binding to K11 diUb.⁴⁶ In addition, only binding of a K6-linked Ub^{prox} would select for the catalytically competent alignment of the Cys and His loops. The human DUB OTULIN uses a similar mechanism of substrate-assisted catalysis to ensure M1 polyUb specificity.⁴⁴ Unlike LotB and LotC, LotA_M also appears to require some form of substrate-assisted catalysis for active site rearrangement, in addition to its requirement for longer polyUb chains.

Helical sub-domains inserted into VR-1 of the OTU domain are a defining feature of Lot-class DUBs. While the basic ~four-helix fold is similar, adaptations to the α1-2 region add versatility to the Ub interface, hence our proposed name A-UBD (Figures 4K and S4E). The A-UBD α1-2 regions of LotA_N, LotA_M, LotB, LotC, as well as OtDUB all play important roles in mediating Ub interactions.^{33,34,50,54} It is remarkable that this domain, now observed in at least 5 cases across two bacterial species, has adopted such distinct Ub interactions. To what extent the A-UBD is incorporated into other regulators of Ub signaling across bacteria, viruses, and eukaryotes will be an interesting area of future research.

During infection, LotA_N and LotA_M regulate distinct polyUb signals on the LCV surface (Figure 7). The close spacing of the two OTU domains (~20 amino acids), however, raises the interesting possibility that they work cooperatively on a large or particularly complex polyUb signal. Though no apparent growth phenotype was observed for the C13S

mutant within LotA_N, functional redundancies among the ~300 secreted *L. pneumophila* effectors often mask phenotypic differences in single-mutant strains. The DUB activity of LotA_M was previously shown to genetically interact with the SidE family of secreted E3 Ub ligases.³⁰ Whether the K6-specific activity of LotA_N functions in concert with other secreted effectors remains to be seen. LotA's two OTU domains with distinct activities and specificities is that they guard different subsets of proteins on the LCV from VCP-dependent extraction and proteasomal degradation. K6 polyUb signals have also been previously tied to the autophagic destruction of mitochondria and bacteria by the E3 ligase Parkin,^{8,57} raising the possibility that LotA acts together with other *L. pneumophila* effectors to restrict host autophagic defenses.⁵⁸ Whether and how LotA_N might fit into this or other K6 signaling networks, and what additional facets of K6 polyUb biology might be uncovered as a result, will be an exciting area of future work.

Limitations of the study

While we could reliably demonstrate the exquisite specificity of LotA_N, even at high enzyme concentration against long polyUb chains, we cannot predict how additional complications such as Ub acetylation or phosphorylation might impact LotA_N's activity or specificity. Furthermore, our testing of LotA_N in UbiCrest analyses of complex, heterotypic, and branched polyUb chains was limited to the few Ub conjugation systems known to assemble K6 linkages. Future applications of LotA_N to the study of K6 polyUb will build upon this foundation and establish its reliability as a steadfast research tool.

Studying the role of LotA's K6 specificity during infection is limited by several parameters. First, the lack of a readily available detection reagent for K6 polyUb necessitated the expression of the exogenous HA-Ub-K6 construct. While we are confident that HA-Ub-K6 is a reliable reporter of K6 polyUb in this case (owing to the strict specificity of LotA_N), expression levels could influence the amount of K6 polyUb we observe. Our ability to assess the relevance of K6-specific DUB activity on *L. pneumophila* growth was also hindered by redundancies among the ~300 secreted effectors. The importance of LotA

activity could also be more apparent in a different host organism, such as amoebae or ciliated protozoa. Regardless, our findings indicate that the study of LotA in mammalian cells will still yield new insights into the signaling roles for this atypical linkage type.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
 - Lead contact
 - Materials availability
 - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
 - Cloning and mutagenesis
 - Protein expression and purification
 - Assembly of polyUb chains
 - Gel-based DUB assays
 - Ub-PA reactivity assays
 - Fluorescence-based DUB assays
 - UbiCRest analysis
 - Protein crystallization and structure determination
 - Legionella strains and culture
 - Transfection and infection
 - Immunofluorescent microscopy
 - Legionella intracellular growth assay
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.molcel.2022.11.022>.

ACKNOWLEDGMENTS

We thank R. Klevit, D. Komander, and T. Mund for sharing expression plasmids; K. Arasaki for sharing the HeLa-FcγRII cell line; and X.T. Bui for assistance with BMDM preparation. We thank members of our laboratories and the Seattle Ub Research Group for helpful discussions. Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, is supported by the US DOE under contract no. DE-AC02-76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE and the NIH (P30GM133894). This work was supported by the Takeda Science Foundation (T. Kubori), MEXT/JSPS KAKENHI grants (19H03469 to T. Kubori), Oregon Health & Science University (J.N.P.), The Collins Medical Trust (J.N.P.), and NIGMS (R35GM142486 to J.N.P.).

AUTHOR CONTRIBUTIONS

Conceptualization, J.N.P.; investigation, G.D.W., T. Kitao, T.G.F., J.V.N., T. Kubori, and J.N.P.; resources, P.P.G.; writing – original draft, G.D.W. and J.N.P.; writing – review & editing, G.D.W. and J.N.P.; supervision, T. Kubori, H.N., and J.N.P.; funding acquisition, T. Kubori and J.N.P.

DECLARATION OF INTERESTS

J.N.P., T.G.F., and J.V.N. are inventors on a licensed technology using LotA to study K6 poly-Ub.

Received: May 12, 2022
Revised: October 13, 2022
Accepted: November 29, 2022
Published: December 19, 2022

REFERENCES

1. Popovic, D., Vucic, D., and Dikic, I. (2014). Ubiquitination in disease pathogenesis and treatment. *Nat. Med.* 20, 1242–1253. <https://doi.org/10.1038/nm.3739>.
2. Clague, M.J., Heride, C., and Urbé, S. (2015). The demographics of the ubiquitin system. *Trends Cell Biol.* 25, 417–426. <https://doi.org/10.1016/j.tcb.2015.03.002>.
3. Komander, D., and Rape, M. (2012). The ubiquitin code. *Annu. Rev. Biochem.* 81, 203–229. <https://doi.org/10.1146/annurev-biochem-060310-170328>.
4. Xu, P., Duong, D.M., Seyfried, N.T., Cheng, D., Xie, Y., Robert, J., Rush, J., Hochstrasser, M., Finley, D., and Peng, J. (2009). Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. *Cell* 137, 133–145. <https://doi.org/10.1016/j.cell.2009.01.041>.
5. Wagner, S.A., Beli, P., Weinert, B.T., Nielsen, M.L., Cox, J., Mann, M., and Choudhary, C. (2011). A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. *Mol. Cell. Proteomics* 10, M111.013284. <https://doi.org/10.1074/mcp.M111.013284>.
6. Roscoe, B.P., Thayer, K.M., Zeldovich, K.B., Fushman, D., and Bolon, D.N.A. (2013). Analyses of the effects of all ubiquitin point mutants on yeast growth rate. *J. Mol. Biol.* 425, 1363–1377. <https://doi.org/10.1016/j.jmb.2013.01.032>.
7. Meza Gutierrez, F., Simsek, D., Mizrak, A., Deutschbauer, A., Braberg, H., Johnson, J., Xu, J., Shales, M., Nguyen, M., Tamse-Kuehn, R., et al. (2018). Genetic analysis reveals functions of atypical polyubiquitin chains. *eLife* 7, 875. <https://doi.org/10.7554/eLife.42955>.
8. Swatek, K.N., and Komander, D. (2016). Ubiquitin modifications. *Cell Res.* 26, 399–422. <https://doi.org/10.1038/cr.2016.39>.
9. Kim, W., Bennett, E.J., Huttlin, E.L., Guo, A., Li, J., Possemato, A., Sowa, M.E., Rad, R., Rush, J., Comb, M.J., et al. (2011). Systematic and quantitative assessment of the ubiquitin-modified proteome. *Mol. Cell* 44, 325–340. <https://doi.org/10.1016/j.molcel.2011.08.025>.
10. Ordureau, A., Sarraf, S.A., Duda, D.M., Heo, J.M., Jedrychowski, M.P., Sviderskiy, V.O., Olszewski, J.L., Koerber, J.T., Xie, T., Beausoleil, S.A., et al. (2014). Quantitative proteomics reveal a feedforward mechanism for mitochondrial Parkin translocation and ubiquitin chain synthesis. *Mol. Cell* 56, 360–375. <https://doi.org/10.1016/j.molcel.2014.09.007>.
11. Elia, A.E.H., Boardman, A.P., Wang, D.C., Huttlin, E.L., Everley, R.A., Dephoure, N., Zhou, C., Koren, I., Gygi, S.P., and Elledge, S.J. (2015). Quantitative proteomic atlas of ubiquitination and acetylation in the DNA damage response. *Mol. Cell* 59, 867–881. <https://doi.org/10.1016/j.molcel.2015.05.006>.
12. Heidelberger, J.B., Voigt, A., Borisova, M.E., Petrosino, G., Ruf, S., Wagner, S.A., and Beli, P. (2018). Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. *EMBO Rep.* 19, e44754. <https://doi.org/10.15252/embr.201744754>.
13. Michel, M.A., Swatek, K.N., Hospenthal, M.K., and Komander, D. (2017). Ubiquitin linkage-specific affirmers reveal insights into K6-linked ubiquitin signaling. *Mol. Cell* 68, 233–246.e5. <https://doi.org/10.1016/j.molcel.2017.08.020>.
14. Bingol, B., Tea, J.S., Phu, L., Reichelt, M., Bakalarski, C.E., Song, Q., Foreman, O., Kirkpatrick, D.S., and Sheng, M. (2014). The mitochondrial deubiquitinase USP30 opposes parkin-mediated mitophagy. *Nature* 510, 370–375. <https://doi.org/10.1038/nature13418>.
15. Cunningham, C.N., Baughman, J.M., Phu, L., Tea, J.S., Yu, C., Coons, M., Kirkpatrick, D.S., Bingol, B., and Corn, J.E. (2015). USP30 and parkin

- homeostatically regulate atypical ubiquitin chains on mitochondria. *Nat. Cell Biol.* 17, 160–169. <https://doi.org/10.1038/ncb3097>.
16. Gersch, M., Gladkova, C., Schubert, A.F., Michel, M.A., Maslen, S., and Komander, D. (2017). Mechanism and regulation of the Lys6-selective deubiquitinase USP30. *Nat. Struct. Mol. Biol.* 24, 920–930. <https://doi.org/10.1038/nsmb.3475>.
 17. Durcan, T.M., Tang, M.Y., Pérusse, J.R., Dashti, E.A., Aguilera, M.A., McLelland, G.L., Gros, P., Shaler, T.A., Faubert, D., Coulombe, B., et al. (2014). USP8 regulates mitophagy by removing K6-linked ubiquitin conjugates from parkin. *EMBO J.* 33, 2473–2491. <https://doi.org/10.15252/embj.201489729>.
 18. Wu-Baer, F., Lagazon, K., Yuan, W., and Baer, R. (2003). The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. *J. Biol. Chem.* 278, 34743–34746. <https://doi.org/10.1074/jbc.C300249200>.
 19. Morris, J.R., and Solomon, E. (2004). BRCA1: BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. *Hum. Mol. Genet.* 13, 807–817. <https://doi.org/10.1093/hmg/ddh095>.
 20. Nishikawa, H., Ooka, S., Sato, K., Arima, K., Okamoto, J., Klevit, R.E., Fukuda, M., and Ohta, T. (2004). Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. *J. Biol. Chem.* 279, 3916–3924. <https://doi.org/10.1074/jbc.M308540200>.
 21. Jäckl, M., Stollmaier, C., Strohäker, T., Hyz, K., Maspero, E., Polo, S., and Wiesner, S. (2018). β -sheet Augmentation Is a Conserved Mechanism of Priming HECT E3 Ligases for ubiquitin Ligation. *J. Mol. Biol.* 430, 3218–3233. <https://doi.org/10.1016/j.jmb.2018.06.044>.
 22. Elliott, P.R. (2016). Molecular basis for specificity of the Met1-linked polyubiquitin signal. *Biochem. Soc. Trans.* 44, 1581–1602. <https://doi.org/10.1042/BST20160227>.
 23. Deol, K.K., Lorenz, S., and Strieter, E.R. (2019). Enzymatic logic of ubiquitin chain assembly. *Front. Physiol.* 10, 835. <https://doi.org/10.3389/fphys.2019.00835>.
 24. Mevissen, T.E.T., and Komander, D. (2017). Mechanisms of deubiquitinase specificity and regulation. *Annu. Rev. Biochem.* 86, 159–192. <https://doi.org/10.1146/annurev-biochem-061516-044916>.
 25. Franklin, T.G., and Pruneda, J.N. (2021). Bacteria make surgical strikes on host ubiquitin signaling. *PLoS Pathog.* 17, e1009341. <https://doi.org/10.1371/journal.ppat.1009341>.
 26. Lin, D.Y.-W., Diao, J., Zhou, D., and Chen, J. (2011). Biochemical and structural studies of a HECT-like ubiquitin ligase from *Escherichia coli* O157:H7. *J. Biol. Chem.* 286, 441–449. <https://doi.org/10.1074/jbc.M110.167643>.
 27. Qiu, J., and Luo, Z.Q. (2017). Hijacking of the host ubiquitin network by *Legionella pneumophila*. *Front. Cell. Infect. Microbiol.* 7, 487. <https://doi.org/10.3389/fcimb.2017.00487>.
 28. Wan, M., Wang, X., Huang, C., Xu, D., Wang, Z., Zhou, Y., and Zhu, Y. (2019). A bacterial effector deubiquitinase specifically hydrolyses linear ubiquitin chains to inhibit host inflammatory signalling. *Nat. Microbiol.* 4, 1282–1293. <https://doi.org/10.1038/s41564-019-0454-1>.
 29. Kitao, T., Nagai, H., and Kubori, T. (2020). Divergence of legionella effectors reversing conventional and unconventional ubiquitination. *Front. Cell. Infect. Microbiol.* 10, 448. <https://doi.org/10.3389/fcimb.2020.00448>.
 30. Kubori, T., Kitao, T., Ando, H., and Nagai, H. (2018). LotA, a *Legionella* deubiquitinase, has dual catalytic activity and contributes to intracellular growth. *Cell. Microbiol.* 20, e12840. <https://doi.org/10.1111/cmi.12840>.
 31. Ma, K., Zhen, X., Zhou, B., Gan, N., Cao, Y., Fan, C., Ouyang, S., Luo, Z.Q., and Qiu, J. (2020). The bacterial deubiquitinase Ceg23 regulates the association of Lys-63-linked polyubiquitin molecules on the *Legionella* phagosome. *J. Biol. Chem.* 295, 1646–1657. <https://doi.org/10.1074/jbc.RA119.011758>.
 32. Schubert, A.F., Nguyen, J.V., Franklin, T.G., Geurink, P.P., Roberts, C.G., Sanderson, D.J., Miller, L.N., Ovaa, H., Hofmann, K., Pruneda, J.N., et al. (2020). Identification and characterization of diverse OTU deubiquitinases in bacteria. *EMBO J.* 39, e105127. <https://doi.org/10.15252/embj.2020105127>.
 33. Shin, D., Bhattacharya, A., Cheng, Y.L., Alonso, M.C., Mehdipour, A.R., van der Heden van Noort, G.J., Ovaa, H., Hummer, G., and Dikic, I. (2020). Bacterial OTU deubiquitinases regulate substrate ubiquitination upon *Legionella* infection. *eLife* 9, e58277. <https://doi.org/10.7554/eLife.58277>.
 34. Liu, S., Luo, J., Zhen, X., Qiu, J., Ouyang, S., and Luo, Z.Q. (2020). Interplay between bacterial deubiquitinase and ubiquitin E3 ligase regulates ubiquitin dynamics on *Legionella* phagosomes. *eLife* 9, e58114. <https://doi.org/10.7554/eLife.58114>.
 35. Hermanns, T., Woiwode, I., Guerreiro, R.F., Vogt, R., Lammers, M., and Hofmann, K. (2020). An evolutionary approach to systematic discovery of novel deubiquitinases, applied to *Legionella*. *Life Sci. Alliance* 3, 3. <https://doi.org/10.26508/lsa.202000838>.
 36. Mevissen, T.E.T., Hospenthal, M.K., Geurink, P.P., Elliott, P.R., Akutsu, M., Arnaudo, N., Ekkebus, R., Kulathu, Y., Wauer, T., Oualid, E.I.F., et al. (2013). OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. *Cell* 154, 169–184. <https://doi.org/10.1016/j.cell.2013.05.046>.
 37. Hospenthal, M.K., Freund, S.M.V., and Komander, D. (2013). Assembly, analysis and architecture of atypical ubiquitin chains. *Nat. Struct. Mol. Biol.* 20, 555–565. <https://doi.org/10.1038/nsmb.2547>.
 38. Hospenthal, M.K., Mevissen, T.E.T., and Komander, D. (2015). Deubiquitinase-based analysis of ubiquitin chain architecture using ubiquitin Chain Restriction (UbiCRest). *Nat. Protoc.* 10, 349–361. <https://doi.org/10.1038/nprot.2015.018>.
 39. Ekkebus, R., van Kasteren, S.I., Kulathu, Y., Scholten, A., Berlin, I., Geurink, P.P., de Jong, A., Goerdal, S., Neeffes, J., Heck, A.J.R., et al. (2013). On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. *J. Am. Chem. Soc.* 135, 2867–2870. <https://doi.org/10.1021/ja309802n>.
 40. Geurink, P.P., El Oualid, F., Jonker, A., Hameed, D.S., and Ovaa, H. (2012). A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents. *Chembiochem* 13, 293–297. <https://doi.org/10.1002/cbic.201100706>.
 41. Békés, M., Rut, W., Kasperkiewicz, P., Mulder, M.P.C., Ovaa, H., Drag, M., Lima, C.D., and Huang, T.T. (2015). SARS hCoV papain-like protease is a unique Lys48 linkage-specific di-distributive deubiquitinating enzyme. *Biochem. J.* 468, 215–226. <https://doi.org/10.1042/BJ20141170>.
 42. Abdul Rehman, S.A., Kristariyanto, Y.A., Choi, S.-Y., Nkosi, P.J., Weidlich, S., Labib, K., Hofmann, K., and Kulathu, Y. (2016). MINDY-1 is a member of an evolutionarily conserved and structurally distinct new family of deubiquitinating enzymes. *Mol. Cell* 63, 146–155. <https://doi.org/10.1016/j.molcel.2016.05.009>.
 43. Virdee, S., Ye, Y., Nguyen, D.P., Komander, D., and Chin, J.W. (2010). Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase. *Nat. Chem. Biol.* 6, 750–757. <https://doi.org/10.1038/nchembio.426>.
 44. Keusekotten, K., Elliott, P.R., Glockner, L., Füll, B.K., Damgaard, R.B., Kulathu, Y., Wauer, T., Hospenthal, M.K., Gyrd-Hansen, M., Krappmann, D., et al. (2013). OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin. *Cell* 153, 1312–1326. <https://doi.org/10.1016/j.cell.2013.05.014>.
 45. Pruneda, J.N., Durkin, C.H., Geurink, P.P., Ovaa, H., Santhanam, B., Holden, D.W., and Komander, D. (2016). The molecular basis for ubiquitin and ubiquitin-like specificities in bacterial effector proteases. *Mol. Cell* 63, 261–276. <https://doi.org/10.1016/j.molcel.2016.06.015>.
 46. Mevissen, T.E.T., Kulathu, Y., Mulder, M.P.C., Geurink, P.P., Maslen, S.L., Gersch, M., Elliott, P.R., Burke, J.E., van Tol, B.D.M., Akutsu, M., et al.

- (2016). Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne. *Nature* 538, 402–405.
47. Michel, M.A., Elliott, P.R., Swatek, K.N., Simicek, M., Pruneda, J.N., Wagstaff, J.L., Freund, S.M.V., and Komander, D. (2015). Assembly and specific recognition of k29- and k33-linked polyubiquitin. *Mol. Cell* 58, 95–109. <https://doi.org/10.1016/j.molcel.2015.01.042>.
 48. Akutsu, M., Ye, Y., Virdee, S., Chin, J.W., and Komander, D. (2011). Molecular basis for ubiquitin and ISG15 cross-reactivity in viral ovarian tumor domains. *Proc. Natl. Acad. Sci. USA* 108, 2228–2233. <https://doi.org/10.1073/pnas.1015287108>.
 49. Grabarczyk, D.B., Petrova, O.A., Deszcz, L., Kurzbauer, R., Murphy, P., Ahel, J., Vogel, A., Gogova, R., Faas, V., Kordic, D., et al. (2021). HUWE1 employs a giant substrate-binding ring to feed and regulate its HECT E3 domain. *Nat. Chem. Biol.* 17, 1084–1092. <https://doi.org/10.1038/s41589-021-00831-5>.
 50. Takekawa, N., Kubori, T., Iwai, T., Nagai, H., and Imada, K. (2022). Structural basis of ubiquitin recognition by a bacterial ovarian tumor deubiquitinase LotA. *J. Bacteriol.* 204, e0037621. <https://doi.org/10.1128/JB.00376-21>.
 51. Juang, Y.-C., Landry, M.-C., Sanches, M., Vittal, V., Leung, C.C.Y., Ceccarelli, D.F., Mateo, A.-R.F., Pruneda, J.N., Mao, D.Y.L., Szilard, R.K., et al. (2012). OTUB1 co-opts Lys48-linked ubiquitin recognition to suppress E2 enzyme function. *Mol. Cell* 45, 384–397. <https://doi.org/10.1016/j.molcel.2012.01.011>.
 52. Holm, L. (2020). Using Dali for protein structure comparison. *Methods Mol. Biol.* 2112, 29–42. https://doi.org/10.1007/978-1-0716-0270-6_3.
 53. Li, Y., Okatsu, K., Fukai, S., and Sato, Y. (2021). Structural basis for specific recognition of K6-linked polyubiquitin chains by the TAB2 NZF domain. *Biophys. J.* 120, 3355–3362. <https://doi.org/10.1016/j.bpj.2021.06.037>.
 54. Berk, J.M., Lim, C., Ronau, J.A., Chaudhuri, A., Chen, H., Beckmann, J.F., Loria, J.P., Xiong, Y., and Hochstrasser, M. (2020). A deubiquitylase with an unusually high-affinity ubiquitin-binding domain from the scrub typhus pathogen *Orientia tsutsugamushi*. *Nat. Commun.* 11, 2343. <https://doi.org/10.1038/s41467-020-15985-4>.
 55. Dorer, M.S., Kirton, D., Bader, J.S., and Isberg, R.R. (2006). RNA interference analysis of *Legionella* in *Drosophila* cells: exploitation of early secretory apparatus dynamics. *PLoS Pathog.* 2, e34. <https://doi.org/10.1371/journal.ppat.0020034>.
 56. Sato, Y., Okatsu, K., Saeki, Y., Yamano, K., Matsuda, N., Kaiho, A., Yamagata, A., Goto-Ito, S., Ishikawa, M., Hashimoto, Y., et al. (2017). Structural basis for specific cleavage of Lys6-linked polyubiquitin chains by USP30. *Nat. Struct. Mol. Biol.* 24, 911–919. <https://doi.org/10.1038/nsmb.3469>.
 57. Manzanillo, P.S., Ayres, J.S., Watson, R.O., Collins, A.C., Souza, G., Rae, C.S., Schneider, D.S., Nakamura, K., Shiloh, M.U., and Cox, J.S. (2013). The ubiquitin ligase parkin mediates resistance to intracellular pathogens. *Nature* 501, 512–516. <https://doi.org/10.1038/nature12566>.
 58. Thomas, D.R., Newton, P., Lau, N., and Newton, H.J. (2020). Interfering with autophagy: the opposing strategies deployed by *Legionella pneumophila* and *Coxiella burnetii* effector proteins. *Front. Cell. Infect. Microbiol.* 10, 599762. <https://doi.org/10.3389/fcimb.2020.599762>.
 59. Arasaki, K., Mikami, Y., Shames, S.R., Inoue, H., Wakana, Y., and Tagaya, M. (2017). *Legionella* effector Lpg1137 shuts down ER-mitochondria communication through cleavage of syntaxin 17. *Nat. Commun.* 8, 15406. <https://doi.org/10.1038/ncomms15406>.
 60. Celada, A., Gray, P.W., Rinderknecht, E., and Schreiber, R.D. (1984). Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. *J. Exp. Med.* 160, 55–74. <https://doi.org/10.1084/jem.160.1.55>.
 61. Kabsch, W. (2010). XDS. *Acta Crystallogr. D Biol. Crystallogr.* 66, 125–132. <https://doi.org/10.1107/S0907444909047337>.
 62. Potterton, L., Agirre, J., Ballard, C., Cowtan, K., Dodson, E., Evans, P.R., Jenkins, H.T., Keegan, R., Krissinel, E., Stevenson, K., et al. (2018). CCP4i2: the new graphical user interface to the CCP4 program suite. *Acta Crystallogr. D Struct. Biol.* 74, 68–84. <https://doi.org/10.1107/S2059798317016035>.
 63. Evans, P.R., and Murshudov, G.N. (2013). How good are my data and what is the resolution? *Acta Crystallogr. D Biol. Crystallogr.* 69, 1204–1214. <https://doi.org/10.1107/S0907444913000061>.
 64. Sheldrick, G.M. (2010). Experimental phasing with SHELXC/D/E: combining chain tracing with density modification. *Acta Crystallogr. D Biol. Crystallogr.* 66, 479–485. <https://doi.org/10.1107/S0907444909038360>.
 65. Langer, G., Cohen, S.X., Lamzin, V.S., and Perrakis, A. (2008). Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. *Nat. Protoc.* 3, 1171–1179. <https://doi.org/10.1038/nprot.2008.91>.
 66. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., and Read, R.J. (2007). Phaser crystallographic software. *J. Appl. Crystallogr.* 40, 658–674. <https://doi.org/10.1107/S0021889807021206>.
 67. Adams, P.D., Afonine, P.V., Bunkóczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.-W., Kapral, G.J., Grosse-Kunstleve, R.W., et al. (2010). Phenix: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* 66, 213–221. <https://doi.org/10.1107/S0907444909052925>.
 68. Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and development of coot. *Acta Crystallogr. D Biol. Crystallogr.* 66, 486–501. <https://doi.org/10.1107/S0907444910007493>.
 69. Berger, K.H., and Isberg, R.R. (1993). Two distinct defects in intracellular growth complemented by a single genetic locus in *Legionella pneumophila*. *Mol. Microbiol.* 7, 7–19. <https://doi.org/10.1111/j.1365-2958.1993.tb01092.x>.
 70. Zuckman, D.M., Hung, J.B., and Roy, C.R. (1999). Pore-forming activity is not sufficient for *Legionella pneumophila* phagosome trafficking and intracellular growth. *Mol. Microbiol.* 32, 990–1001. <https://doi.org/10.1046/j.1365-2958.1999.01410.x>.
 71. Coers, J., Vance, R.E., Fontana, M.F., and Dietrich, W.F. (2007). Restriction of *Legionella pneumophila* growth in macrophages requires the concerted action of cytokine and Naip5/Ipf1 signalling pathways. *Cell. Microbiol.* 9, 2344–2357. <https://doi.org/10.1111/j.1462-5822.2007.00963.x>.
 72. Horwitz, M.A. (1983). The Legionnaires' disease bacterium (*Legionella pneumophila*) inhibits phagosome-lysosome fusion in human monocytes. *J. Exp. Med.* 158, 2108–2126. <https://doi.org/10.1084/jem.158.6.2108>.
 73. Kelley, L.A., Mezulis, S., Yates, C.M., Wass, M.N., and Sternberg, M.J.E. (2015). The Phyre2 web portal for protein modeling, prediction and analysis. *Nat. Protoc.* 10, 845–858. <https://doi.org/10.1038/nprot.2015.053>.
 74. Studier, F.W. (2005). Protein production by auto-induction in high density shaking cultures. *Protein Expr. Purif.* 41, 207–234. <https://doi.org/10.1016/j.pep.2005.01.016>.
 75. Wilkinson, K.D., Gan-Erdene, T., and Kolli, N. (2005). Derivatization of the C-terminus of ubiquitin and ubiquitin-like proteins using intein chemistry: methods and uses. *Meth. Enzymol.* 399, 37–51. [https://doi.org/10.1016/S0076-6879\(05\)99003-4](https://doi.org/10.1016/S0076-6879(05)99003-4).
 76. Michel, M.A., Komander, D., and Elliott, P.R. (2018). Enzymatic assembly of ubiquitin chains. *Methods Mol. Biol.* 1844, 73–84. https://doi.org/10.1007/978-1-4939-8706-1_6.
 77. Pruneda, J.N., and Komander, D. (2019). Evaluating enzyme activities and structures of DUBs. *Meth. Enzymol.* 618, 321–341. <https://doi.org/10.1016/bs.mie.2019.01.001>.
 78. Basters, A., Geurink, P.P., El Oualid, F., Ketscher, L., Casutt, M.S., Krause, E., Ovaa, H., Knobeloch, K.-P., and Fritz, G. (2014). Molecular characterization of ubiquitin-specific protease 18 reveals substrate specificity for

- interferon-stimulated gene 15. FEBS J. 287, 1918–1928. <https://doi.org/10.1111/febs.12754>.
79. Vijay-Kumar, S., Bugg, C.E., and Cook, W.J. (1987). Structure of ubiquitin refined at 1.8 Å resolution. J. Mol. Biol. 194, 531–544. [https://doi.org/10.1016/0022-2836\(87\)90679-6](https://doi.org/10.1016/0022-2836(87)90679-6).
80. Merriam, J.J., Mathur, R., Maxfield-Boumil, R., and Isberg, R.R. (1997). Analysis of the Legionella pneumophila flil gene: intracellular growth of a defined mutant defective for flagellum biosynthesis. Infect. Immun. 65, 2497–2501. <https://doi.org/10.1128/iai.65.6.2497-2501.1997>.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-Ubiquitin (clone Ubi-1)	MilliporeSigma	Cat#MAB1510-I; RRID: AB_2180556
Anti-Mouse IgG, HRP conjugate	MilliporeSigma	Cat#12-349; RRID: AB_390192
Anti-Legionella	Scrum	Cat#17457
Anti-Legionella	BioAcademia	Cat#64-100
Anti-HA	MBL	Cat#561; RRID: AB_591839
Anti-VCP	Abcam	Cat#ab11433; RRID: AB_298039
Anti-Rabbit IgG, Alexa488 conjugate	Invitrogen	Cat#A11034; RRID: AB_2576217
Anti-Rat IgG, Alexa 568 conjugate	Invitrogen	Cat#A11077; RRID_2534121
Anti-Mouse IgG, Alexa488 conjugate	Invitrogen	Cat#A11029; RRID: AB_2534088
Anti-Rabbit IgG, RhodamineRedX conjugate	Invitrogen	Cat#R6394; RRID: AB_2556551
Bacterial strains		
See Table S1 for a full list of bacterial strains		
Chemicals and recombinant proteins		
ATTO488-maleimide	ATTO-TEC	Cat#AD488
K27 diUb	UbiQ	Cat#UbiQ-015
K11 tetraUb	R&D Systems	Cat#UC-45-025
Deposited data		
Crystal structure of LotA _N	This study	PDB: 7UYG
Crystal structure of LotA _N bound to K6 diUb	This study	PDB: 7UYH
Experimental models: Cell lines		
Human: HeLa-FcγRII	Laboratory of K. Arasaki	Arasaki et al. ⁵⁹
Mouse: Bone marrow-derived macrophages	A/J mice	Celada et al. ⁶⁰
Oligonucleotides		
See Table S1 for a full list of oligonucleotides		
Recombinant DNA		
See Table S1 for a full list of recombinant DNA		
Software and algorithms		
XDS	Kabsch ⁶¹	Version Jan 31, 2020
CCP4i2	Potterton et al. ⁶²	Version 7.1.004
Aimless	Evans and Murshudov ⁶³	Version 0.7.4
SHELXC/D/E	Sheldrick ⁶⁴	N/A
ARP/wARP	Langer et al. ⁶⁵	Version 8.0
Phaser	McCoy et al. ⁶⁶	Version 2.8.3
PHENIX	Adams et al. ⁶⁷	Version 1.17.1
Coot	Emsley et al. ⁶⁸	Version 0.9
Pymol	www.pymol.org	Version 2.2.2
Prism	GraphPad	Version 9

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Jonathan N. Pruneda (pruneda@ohsu.edu).

Materials availability

All reagents generated from this study are available from the [lead contact](#) upon request.

Data and code availability

- Coordinates and structure factors for the apo and K6 diUb-bound LotA_N structures have been deposited in the Protein Data Bank under accession codes 7UYG and 7UYH, respectively, and will be publicly available as of the date of publication.
- This paper does not report original code.
- Any additional information required to reanalyze the data reported in this paper is available from the [lead contact](#) upon request.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

TOP10 *Escherichia coli* (ThermoFisher) were used for all cloning and plasmid propagation. Rosetta (DE3) *E. coli* (MilliporeSigma) were used for all recombinant protein expression. DH5 α *E. coli* (BEI Resources) were used for allelic exchange. All *E. coli* strains were grown at 37°C in Luria-Bertani (LB) media containing appropriate antibiotics.

Legionella pneumophila Philadelphia-1 (Lp01) were used as the wild-type strain in our studies.⁶⁹ All mutations were introduced into the base *L. pneumophila* strain by allelic exchange and confirmed by PCR and DNA sequencing.⁷⁰ Luciferase-expressing strains were constructed as described previously.⁷¹ All *L. pneumophila* strains were grown at 37°C in liquid N-(2-acetamido)-2-aminoethanesulfonic acid (ACES; MilliporeSigma)-buffered yeast extract (AYE) media or on charcoal-yeast extract (CYE) plates, as described previously.⁷²

HeLa-Fc γ RII cells (a kind gift from K. Arasaki at Tokyo University of Pharmacy and Life Sciences) were grown in Minimum Essential Medium α (MEM α ; Gibco) supplemented with 10% fetal bovine serum (FBS) and 400 μ g/mL hygromycin (Nacalai).⁵⁹

Murine bone marrow-derived macrophages were prepared from A/J mice (A/JJmsSlc; Japan SLC) and maintained in RPMI 1640 Medium (GIBCO) supplemented with 5% L cell supernatant and 10% FBS as described previously.⁶⁰

METHOD DETAILS

Cloning and mutagenesis

The *lotA* gene was cloned from *Legionella pneumophila* Philadelphia-1 genomic DNA. Initial construct design was performed using Phyre2⁷³ and the LotA_M crystal structure,⁵⁰ yielding construct boundaries of 1–300 and 287–543 for LotA_N and LotA_M, respectively. To support crystallization, additional C-terminal truncations of LotA_N led to the 1–294 construct used for determination of the apo LotA_N structure. Based on the apo structure, an additional LotA_N construct encoding amino acids 1–276 was used for determination of the K6 diUb-bound structure. All LotA constructs were cloned into the pOPINB vector, which encodes an N-terminal His tag followed by a 3C protease cleavage site. Cloning and mutagenesis were performed using Phusion DNA Polymerase (New England BioLabs) and TOP10 *E. coli* (ThermoFisher).

Protein expression and purification

All pOPINB-LotA constructs were expressed and purified similarly. Transformed Rosetta (DE3) *E. coli* were grown in Luria broth containing 35 μ g/mL chloramphenicol and 50 μ g/mL kanamycin at 37°C until an optical density (600 nm) of 0.6–0.8. Cultures were cooled to 18°C and induced with 0.2 mM IPTG for an additional 20 hours. Cells were harvested by centrifugation and resuspended in 25 mM Tris, 200 mM NaCl, 2 mM β -mercaptoethanol, pH 8.0 (Buffer A). Following a freeze-thaw cycle, cells were incubated on ice with lysozyme, DNase, and SigmaFAST protease inhibitor cocktail (MilliporeSigma) prior to lysis by sonication. Clarified lysates were applied to HisPur cobalt affinity resin (ThermoFisher) and washed with Buffer A prior to elution with Buffer A containing 300 mM imidazole. Eluted proteins were cleaved with 3C protease overnight during dialysis back to Buffer A at 4°C. Cleaved LotA proteins were concentrated using 10K MWCO Amicon centrifugal filters (MilliporeSigma) and applied to a HiLoad Superdex 75 pg size exclusion chromatography column (Cytiva) equilibrated in 25 mM Tris, 200 mM NaCl, 5 mM DTT, pH 8.0. Fractions were evaluated for purity by SDS PAGE, collected, concentrated, and quantified by absorbance (280 nm) prior to flash freezing and storage at -80°C.

Untagged Ub constructs were expressed from the pET-17b vector. Transformed Rosetta (DE3) *Escherichia coli* were grown by auto-induction in a modified ZYM-5052 media⁷⁴ containing 35 μ g/mL chloramphenicol and 100 μ g/mL ampicillin at 37°C for 24–48 h. Cells were harvested by centrifugation, resuspended, and lysed as above for LotA. Clarified lysates were acidified by dropwise addition of 70% perchloric acid to a final concentration of 0.5%. The mixture was allowed to stir on ice for 1–2 h prior to centrifugation. The supernatant was dialyzed against 50 mM sodium acetate, pH 4.5 overnight at 4°C. The protein was applied to a HiPrep SP FF 16/10 cation exchange column (Cytiva), washed with additional 50 mM sodium acetate, pH 4.5, and eluted over a linear gradient to a matched buffer containing 500 mM NaCl. Fractions were evaluated for purity by SDS PAGE, pooled, and dialyzed against 25 mM Tris, 200 mM NaCl, pH 8.0 overnight at 4°C. If necessary, further purification was performed using a HiLoad Superdex 75 pg size exclusion chromatography column (Cytiva) equilibrated in 25 mM Tris, 200 mM NaCl, pH 8.0. Purified Ub was concentrated using 3K MWCO Amicon centrifugal filters (MilliporeSigma), quantified by absorbance (280 nm), and flash frozen for storage at either -20°C or -80°C.

The Ub-PA activity-based probes were prepared using intein chemistry as described previously.⁷⁵ Rosetta (DE3) *Escherichia coli* transformed with pTXB1-Ub(1-75) were grown in Luria broth containing 35 $\mu\text{g/mL}$ chloramphenicol and 100 $\mu\text{g/mL}$ ampicillin at 37°C until an optical density (600 nm) of 0.6–0.8. Cultures were cooled to 18°C and induced with 0.5 mM IPTG for an additional 20 hours. Cells were harvested by centrifugation and resuspended in 20 mM HEPES, 50 mM sodium acetate, 75 mM NaCl, pH 6.5 (Buffer B). After a freeze-thaw cycle, cells were incubated on ice with DNase, SigmaFAST protease inhibitor cocktail (MilliporeSigma), and PMSF prior to lysis by sonication. The clarified lysate was applied to chitin resin (New England BioLabs) and allowed to bind at 37°C for 2 h. The resin was washed with Buffer B, followed by a high salt wash with Buffer B containing 500 mM NaCl, followed by a final wash with Buffer B. The Ub-MesNa was allowed to form and elute from the chitin resin for 42 h at room temperature, following addition of Buffer B containing 100 mM MesNa. The eluted protein was concentrated using 3K MWCO Amicon centrifugal filters (MilliporeSigma) and applied to a HiLoad Superdex 75 pg size exclusion chromatography column (Cytiva) equilibrated in Buffer B. Fractions containing Ub-MesNa were evaluated for purity by SDS PAGE and pooled. To convert Ub-MesNa to Ub-PA, propargylamine hydrochloride was added in 1000-fold excess and, following adjustment of the pH to 8.5, incubated at room temperature for 3 h. The reaction was dialyzed against 25 mM Tris, 200 mM NaCl, pH 8.0 overnight at 4°C. The final product was concentrated using 3K MWCO Amicon centrifugal filters (MilliporeSigma), quantified by absorbance (280 nm), and stored on ice during immediate use.

Assembly of polyUb chains

All diUb and tetraUb chains were assembled and purified according to published methods,⁷⁶ with the exception of K27 diUb and K11 tetraUb, which were purchased from UbiQ and R&D Systems, respectively. K6 diUb for fluorescent labeling or for experiments that incorporate Ub^{prox} mutations were assembled using a “capped” strategy that allows directed formation of K6-linked diUb from dedicated donor and acceptor Ub moieties that are incorporated as Ub^{dist} and Ub^{prox}, respectively. The dedicated donor Ub construct incorporated K6R and K48R mutations, but retained an intact C-terminus. The dedicated acceptor Ub construct incorporated a K48R mutation and lacked the C-terminal LRGG motif. Effects of Ub^{prox} mutation were assessed by incorporating additional mutations into the dedicated acceptor Ub construct. Alternatively, a Ub^{prox} for fluorophore labeling was incorporated with an acceptor Ub construct that coupled a deletion of G76 with a G75C mutation. Equimolar amounts of donor and acceptor Ub variants were combined with 100 nM UBE1, 600 nM UBE2L3, 10 μM NleL, and 10 mM ATP in buffer containing 40 mM Tris, 10 mM MgCl₂, 0.5 mM DTT, pH 8.5. Reactions were incubated at 37°C for 16 h and subsequently quenched by addition of 10 mM DTT and 50-fold dilution into 50 mM sodium acetate, pH 4.5. The reactions were applied to a HiPrep SP FF 16/10 cation exchange column (Cytiva), washed with additional 50 mM sodium acetate, pH 4.5, and eluted over a linear gradient to a matched buffer containing 500 mM NaCl. Fractions were evaluated for purity by SDS PAGE, pooled, and dialyzed against 25 mM Tris, 200 mM NaCl, pH 8.0 overnight at 4°C. The diUb product was concentrated using 3K MWCO Amicon centrifugal filters (MilliporeSigma), quantified by absorbance (280 nm), flash frozen, and stored at either -20°C or -80°C.

Fluorescent K6 diUb was prepared using the “capped” strategy described above, which allows specific labeling of a cysteine incorporated at position 75 of Ub^{prox}. Purified K6 diUb was diluted to 50 μM in 25 mM sodium phosphate, 150 mM NaCl, 10 mM DTT, pH 7.4 and incubated at room temperature for 30 min. The diUb was subsequently buffer exchanged into 25 mM sodium phosphate, 150 mM NaCl, pH 7.4 over a PD-10 desalting column (Cytiva). ATTO488-maleimide (ATTO-TEC) was added in 5-fold molar excess to 1 mL of the desalted K6 diUb, and incubated at room temperature in the dark for 18 h. The labeled K6 diUb was again desalted to remove excess fluorophore, quantified by absorbance (488 nm), and flash frozen for storage at -80°C.

Gel-based DUB assays

Gel-based DUB assays were performed according to published methods.⁷⁷ DUBs were prepared at 2X concentration in 25 mM Tris, 150 mM NaCl, 10 mM DTT, pH 7.4 and incubated at room temperature for 10 min. Equal volumes of 2X DUB and either 10 μM diUb or 5 μM tetraUb were mixed and incubated at 37°C. Samples were quenched in Laemmli sample buffer containing 0.2 M dithiothreitol (DTT) and analyzed by SDS PAGE.

Ub-PA reactivity assays

Ub-PA reactivity assays were performed according to published methods.⁷⁷ DUBs were diluted to 10 μM in 25 mM Tris, 150 mM NaCl, 10 mM DTT, pH 7.4 and incubated at room temperature for 10 min. Equal volumes of 2X DUB and 100 μM Ub-PA were mixed and allowed to react at room temperature for up to 18 h, prior to being quenched in Laemmli sample buffer containing 0.2 M DTT and analyzed by SDS PAGE. For rescue experiments with the F4A Ub-PA variant, 25 μM wild-type or F4A Ub was added to the above reaction.

Fluorescence-based DUB assays

Ub- and Ubi-KG(TAMRA) substrates were prepared as previously described.^{40,78} Cleavage of the Ub- and Ubi-KG(TAMRA) substrates was monitored by fluorescence polarization according to published methods.⁷⁷ Enzymes and substrates were prepared at 2X concentration in 25 mM Tris, 100 mM NaCl, 5 mM β -mercaptoethanol, 0.1 mg/mL BSA, pH 7.4 and mixed 1:1 to initiate the reaction. All substrates were held at 50 nM concentration, while protease concentrations were adjusted according to their specific activities. Fluorescence polarization was recorded using a BMG LabTech ClarioStar plate reader with an excitation wavelength of 540 nm, an LP 566 nm dichroic mirror, and an emission wavelength of 590 nm. Reactions were performed in Greiner 384-well

small-volume HiBase microplates with 20 μ L reaction volumes. Three technical replicates were performed for each reaction, with additional wells containing KG(TAMRA) and Ub/Ubl-KG(TAMRA) as positive and negative controls, respectively. Fluorescence polarization was recorded once per minute over a 1–2 h time period. Data collected from the positive and negative control wells were used to convert fluorescence polarization measurements to fraction of substrate remaining.

DUB assays using the ATTO488-labeled K6 diUb substrate were performed as above, with minor changes. Fluorescence polarization was monitored using an excitation wavelength of 482 nm, an LP 504 nm dichroic mirror, and an emission wavelength of 530 nm. Assay concentrations were 10 nM LotA_N and 50 nM ATTO488-labeled K6 diUb, except for the LotA_N triple-mutants, which were also assayed at a higher enzyme concentration of 1 μ M. ATTO488-labeled monoUb and diUb were used as positive and negative controls, respectively, and used to convert fluorescence polarization measurements to fraction of substrate remaining. To determine Michaelis-Menten parameters, LotA_N concentration was held at 4 nM and initial rates of cleavage were determined from the linear range of data produced over the first 15–25 minutes of the reaction, across a range of substrate concentrations from 100 nM to 50.1 μ M. All substrate concentrations maintained a fixed, 100 nM concentration of ATTO488-labeled K6 diUb, while unlabeled K6 diUb (shown to be hydrolyzed equally well) was used for the remainder. Three technical replicates were performed for each reaction, and three separate trials were performed for each K6 diUb concentration. Positive and negative control measurements were used to convert fluorescence polarization data to amount of substrate consumed, which was used to derive initial rates. Prism 9 was used for Michaelis-Menten analysis of the initial rate data.

UbiCrest analysis

Linkage-specific polyUb chains were assembled according to published methods.⁷⁶ NleL and HUWE1 chain assemblies were performed at 37°C for 2 h in 25 mM Tris, 150 mM NaCl, 10 mM MgCl₂, 0.5 mM DTT, pH 7.4 using 375 nM UBE1, 1.5 μ M Lys-less UBE2L3, 5 mM ATP, and either 3.75 μ M NleL (aa 170–782) or 15 μ M HUWE1 (aa 3993–4373). Prior to DUB treatment, all polyUb assembly reactions were quenched by addition of 50 mM EDTA and 5 mM DTT. DUBs were diluted to 10 μ M in 25 mM Tris, 150 mM NaCl, 10 mM DTT, pH 7.4 and incubated at room temperature for 10 min. Equal volumes of polyUb assembly and DUB were mixed and incubated at 37°C for 2 h, prior to quenching in Laemmli sample buffer containing 0.2 M DTT. Reactions were resolved by SDS PAGE prior to transfer onto PVDF membranes using a Trans-Blot Turbo system (BioRad). Membranes were blocked at room temperature for 30 minutes with TBS-T (Tris-buffered Saline containing 0.1% Tween-20) containing 5% milk, then incubated with primary anti-Ub antibody (MilliporeSigma, MAB1510-I; 1:1,000 dilution) at 4°C overnight. Membranes were washed in TBS-T and incubated with secondary antibody (MilliporeSigma, #12-349; 1:5,000 dilution) at room temperature for 1 hour before performing additional TBS-T washes and detection using Clarity ECL reagent (BioRad).

Protein crystallization and structure determination

LotA_N (1–294), LotA_N (1–276), and K6 diUb were prepared as described above and exchanged into 25 mM Tris, 125 mM NaCl, 5 mM DTT, pH 7.4. LotA_N (1–294) was concentrated to 12 mg/mL and crystallized in hanging drop format with 30% PEG 2K MME, 0.2 M KI, 0.1 M MES pH 6.5 at 20°C in a 1 μ L drop with 1:1 protein:precipitant ratio. LotA_N (1–276) was mixed with an equimolar amount of K6 diUb and concentrated using a 3K MWCO Amicon centrifugal filter (MilliporeSigma) to a total protein concentration of 8 mg/mL (determined by Bradford Assay). The protein complex was crystallized in hanging drop format with 25% PEG 3350, 10% ethylene glycol, 0.2 M KSCN, 0.1 M MES pH 5.5 at 20°C in a 1 μ L drop with 1:1 protein:precipitant ratio. Apo LotA_N crystals were cryoprotected in mother liquor containing 12.5% glycerol, while complex LotA_N crystals were cryoprotected in mother liquor containing 25% glycerol prior to vitrification.

Diffraction data were collected at the Stanford Synchrotron Radiation Lightsource (SSRL), beamline 9-2. Images were integrated using XDS⁶¹ and scaled using Aimless.⁶³ The apo LotA_N (1–294) structure was determined by SAD using the SHELXC/D/E pipeline in CCP4i2,^{62,64} based on anomalous signal arising from bound iodide ions that were present in the crystallization condition. Automated model building was performed using ARP/wARP,⁶⁵ followed by iterative rounds of manual model building in COOT and refinement in PHENIX.^{67,68} Residues 2–275 could be confidently modeled into the electron density. The complex LotA_N (1–276) structure bound to K6 diUb was determined by molecular replacement with Phaser in CCP4i2, using the apo LotA_N and Ub (PDB: 1UBQ) structures.^{62,66,79} Model building and refinement were performed as above using COOT and PHENIX.^{67,68} All figures were generated using PyMOL (www.pymol.org).

Legionella strains and culture

L. pneumophila strains used in this study are listed in Table S1. Point mutations in genomic *lotA* were introduced by a gene knock-in method, whereby mutated *lotA* genes were integrated into the Δ *lotA* strain at the endogenous locus.³⁰ Plasmids used for the integration were constructed based on pSR47S- Δ *lotA*,³⁰ which contains homologous regions upstream and downstream of the endogenous *lotA* locus inserted into the pSR47S gene-replacement vector as follows.⁸⁰ The linearized pSR47S- Δ *lotA* was generated by PCR using primers lpg2248KI-1 and lpg2248KI-2. Fragments of the mutated *lotA* genes were obtained by PCR using primers lpg2248KI-3 and lpg2248KI-4 from pMMB207-3xFLAG-LotA C13S,³⁰ 3xFLAG-LotA C303S,³⁰ 3xFLAG-LotA C13S/C303S,³⁰ pOPINB-LotA F120A/R145L/A193P, and pOPINB-LotA L128R/R145L/A193P. The vector and *lotA* fragments were ligated using Gibson assembly, and the resulting plasmids were transformed into *E. coli* DH5 α pir. The allelic exchange was conducted as described previously.⁷⁰ The genomic mutations of *lotA* were validated by PCR and subsequent DNA sequencing. The *L. pneumophila* strains were

grown at 37°C in liquid N-(2-acetamido)-2-aminoethanesulfonic acid (ACES; MilliporeSigma)-buffered yeast extract (AYE) media or on charcoal-yeast extract (CYE) plates, as described previously.⁷²

Transfection and infection

HeLa-FcγRII cells were seeded on cover slips in 24-well tissue culture plates at 5×10^4 cells per well 24 h before transfection. If necessary, transfection was performed using Lipofectamine2000 (Invitrogen) and 500 ng of pRK5-HA-Ub-K6 (Addgene, #22900) for 24 h according to the manufacturer's recommendation. Because of the lysine-to-arginine mutations and the encoded N-terminal epitope tag, HA-Ub-K6 can only be utilized for a) monoubiquitination, b) as a distal capping Ub on the end of a polyUb chain, or c) incorporation into a K6-linked chain. Owing to its stringent requirement for substrate-assisted catalysis, *LotA_N* would only be able to hydrolyze HA-Ub-K6 that is incorporated into K6-linked chains. For infection, *L. pneumophila* was cultivated for 24 h in AYE media (with starting A_{600} of 0.2) at 37°C with shaking. The cells were infected with the *Legionella* strains opsonized with anti-*Legionella* rat antibody (Scrum, #17457; 1:3,000 dilution) or with anti-*Legionella* rabbit antibody (BioAcademia, #64-100; 1:3,000 dilution) at a multiplicity of infection (MOI) of 2. After adding bacteria to the cells, the plates were centrifuged at $200 \times g$ to precipitate bacteria onto the layer of cells and were immediately warmed in a 37°C water-bath by floating for 5 min and then placed in a CO₂ incubator at 37°C. At 1 h after infection, the infected cells were washed three times with prewarmed Dulbecco's Phosphate Buffered Saline (DPBS; MilliporeSigma) to remove the extracellular bacteria and refreshed with prewarmed media, then incubation was resumed at 37°C in a CO₂ incubator. At 4 h after infection, the cells were washed three times with DPBS and fixed with 4% (w/v) paraformaldehyde for 20 min.

Immunofluorescent microscopy

For detection of HA-Ub-K6, the fixed HeLa-FcγRII cells on coverslips were permeabilized by treating with cold methanol for 60 sec and washed three times with DPBS. The samples were blocked with 2% (v/v) goat serum in DPBS and treated with anti-HA rabbit antibody (MBL, #561) at 1:200 dilution for 90 min. After three times washing with DPBS, the samples were treated with anti-*Legionella* rat antibody (Scrum, #17457; 1:3,000 dilution) for 60 min. After three times washing with DPBS, the samples were treated with secondary fluorescent antibodies, Alexa 488 goat anti-rabbit IgG (Invitrogen, #A11034; 1:500 dilution) and Alexa 568 goat anti-rat IgG (Invitrogen, #A11077; 1:500 dilution), for 40 min. After washing three times with DPBS, the coverslips were rinsed with distilled water and mounted on glass slides with ProLong™ Diamond Antifade Mountant with DAPI (Invitrogen, P36962). For detection of VCP, the fixed HeLa-FcγRII cells on coverslips were permeabilized and blocked by treating with 0.2% (v/v) Triton X-100 and 2% (v/v) goat serum in DPBS for 20 min. After washing three times in DPBS, the samples were then treated with anti-VCP mouse antibody (Abcam, #ab11433; 1:200 dilution) for 90 min, followed by treatment with anti-*Legionella* antibody (BioAcademia, #64-100; 1:3,000 dilution) for 60 min. After three additional washes in DPBS, the samples were treated with secondary fluorescent antibodies, Alexa 488 goat anti-mouse IgG (Invitrogen, #A411029; 1:500 dilution) and Rhodamine Red-X anti-rabbit IgG (Invitrogen, #R6394; 1:1,000 dilution), for 40 min. After three final washes in DPBS, the coverslips were rinsed with distilled water and mounted on glass slides with ProLong™ Diamond Antifade Mountant with DAPI (Invitrogen, P36962). Images were collected with an inverted microscope (TE2000-U; Nikon) equipped with a digital ORCA-ERA camera (Hamamatsu). Images were blinded and quantified by manual counting of immunostained LCVs. In the case of experiments involving HA-Ub-K6, only LCVs contained within cells expressing the HA-Ub-K6 construct were used for counting.

Legionella intracellular growth assay

The luminescent *L. pneumophila* growth assay was conducted as described previously.³⁰ Mouse BMDMs (4×10^4 cells per well) were prepared in a 96-well plate (#353296; Falcon) one day before infection. Cells were infected with *L. pneumophila* strains expressing luciferase at a MOI of 0.5, then incubated at 37°C under 5% CO₂. Intracellular bacterial growth was monitored by luminescence using a microplate reader (GloMax Explorer; Promega).

QUANTIFICATION AND STATISTICAL ANALYSIS

Welch's t tests were performed on all microscopy quantifications using Prism 9 software with data from three independent infection experiments. P values less than 0.05 were considered significant, with annotations as follows: * ($p < 0.05$), ** ($p < 0.01$), *** ($p < 0.001$), **** ($p < 0.0001$).